Johnson & Johnson may have a real winner on their hands. Their drug Zytiga is already approved for use in very late stage prostate cancer – after Casodex/Lupron and chemotherapy fail. On average it extends life a few months.
They ran a clinical trial where the drug was used much earlier, before chemotherapy was started. The results were so good they halted the clinical trial to give the control group Zytiga as well. Pain levels were significantly reduced and life was extended considerably (because they halted the trial early they were unable to estimate with precision how much longer life was extended).
Definitely will be discussing this with my oncologist. My impression is I would start about the time bone pain from the cancer starts.
Bloomberg’s report of the drug can be found here.